Does TMDX pay a dividend and is it safe?

TransMedics Group Inc. (TMDX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / TMDX / dividends

AXGN (53) CNMD (62) ITGR (67) LIVN (66) ⌘ Pro Terminal →

TransMedics Group Inc. (TMDX) Dividend Safety Gauge & 10-Year DRIP Compounder

$65.99 -1.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $65.67

TransMedics Group Inc. (TMDX) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $2.29B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TMDX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TMDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, TransMedics Group Inc. (NASDAQ: TMDX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $65.99 (-1.68% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, TMDX ranks #157 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TMDX compare to AXGN and CNMD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), TMDX carries a Roarable C- (61/100 RQD), trailing P/E of 12.2x, gross margin of 59.9%, and ROIC of 18.1%. By comparison, AXGN (Axogen Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -2.6%, cap $2.95B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.32B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TMDX?

▼

Per TMDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001756262), TransMedics Group Inc. generated $605.5M in revenue (+37.1% YoY), $190.3M in net income, and $133.6M in free cash flow against $1.07B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (59.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $65.67 (-0.49%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 22.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TMDX)Realized 20D OHLCV Swing Band: ±9.4%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY TMDX SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (26% of score)

Altman Z-Score 3.50 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$79.14-5.5% Next Q

Q2 (-2Q)

Grade B-$74.75-6.7% Next Q

Q3 (-1Q)

Grade C+$69.73-5.4% Next Q

Current

Grade C-$65.99+0.5% Hist 90D α

Trajectory: B- (69) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TMDX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, TMDX faces multiple-compression risk if 12.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 57.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($80.55) or 200D SMA ($93.71) invalidates the momentum regime and cuts Target Base ($66.88) toward Bear Floor ($52.17).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TMDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TMDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in TMDX & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on TMDX and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TMDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.03%🛡️ HOLDING TREND SUPPORT

2026-11-03O $67.12H $67.12L $65.99C $65.99VOL 900.1K

RES: $111.9SUP: $64.52SMA50: $80.55SMA200: $93.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TMDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TMDX Butterfly Map → + Track TMDX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

2.8%/yr Implied 5Y Growth

vs. +37.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TMDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TMDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TMDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TMDX)

Health Care Rank #157 of 1015 ⚔️ AXGN vs TMDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TMDX vs. AXGN, CNMD, ITGR, LIVN)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, TransMedics Group Inc. (TMDX) ranks #157 by composite RQD confidence (61/100, grade C-) and #233 by equity capitalization ($2.29B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. ITGR currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with TMDX at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TMDX ACTIVE TransMedics Group Inc.	C-	61/100	12.2x	59.9%	18.1%	-1.68%	$2.29B	Benchmark Subject
AXGN Axogen Inc.	D+	53/100	—	74.3%	-2.6%	-0.52%	$2.95B	/axgn-vs-tmdx →
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-3.13%	$1.32B	/cnmd-vs-tmdx →
ITGR Integer Holdings Corporation	C+	67/100	41.8x	27.0%	6.0%	+0.06%	$4.30B	/itgr-vs-tmdx →
LIVN LivaNova PLC	C+	66/100	—	67.7%	17.3%	-2.81%	$4.35B	/livn-vs-tmdx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001756262 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TransMedics Group Inc. (TMDX) reported GAAP revenue of $605.5M (+37.1% vs. FY2024 revenue of $441.5M , and +150.6% cumulative change since FY2023) , GAAP net income of $190.3M, operating cash flow of $192.8M, and free cash flow of $133.6M (+265.0% YoY). On the balance sheet, TMDX closed FY2025 with $1.07B in total assets against $0 in total debt (Altman Z-Score: 3.50, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$605.5M	$190.3M	$192.8M	$133.6M	$1.07B	—
FY2024 (FY)	2024-12-31	$441.5M	$35.5M	$48.8M	-$80.9M	$804.1M	—
FY2023 (FY)	2023-12-31	$241.6M	-$25.0M	-$13.0M	-$13.0M	—	—

3. TMDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TMDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TMDX compare to AXGN and CNMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TMDX?

Where is TMDX trading relative to its 50-day, 200-day, and 52-week technical levels?

TMDX last traded at $65.99 (-1.68% on volume of 900,114 shares), positioning the stock -18.08% below its 50-day simple moving average ($80.55) and -29.58% below its 200-day simple moving average ($93.71). Across its 52-week range of $60.10 to $156.00, TMDX sits at the 6.1% percentile with a 14-day RSI of 30.8 (OVERSOLD (<32)) and an implied next-earnings move of ±9.4% ($59.79 to $72.19).

Direct Sub-Reports: TMDX RQD Cockpit TMDX 12M Forecast TMDX Earnings & Move TMDX Dividends & DRIP TMDX Insiders & 13F TMDX Whale Options TMDX Profit Sankey TMDX News & Why

ROARABLE RATING BRIEF • RQD 61/100 (C-) ✓ SEC XBRL & RQD VERIFIED

TMDX — TransMedics Group Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

TransMedics Group Inc. (TMDX) earns a live Roarable RQD composite score of 61/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $65.99 (-1.68% 1D, market capitalization $2.29B).

Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 18.1%, gross margin of 59.9%, operating margin of 17.9%, and free cash flow yield of 5.74%.
Whale 13F & Options Flow (4/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.50, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

TransMedics Group Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $2.3B. The reported margins (gross 59.9%, operating 17.9%, net 31.4%) are per the Market Data section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TransMedics Group Inc. (TMDX) reported $605.5M in annual revenue (up from $441.5M in FY2024, +37.1% YoY) and $190.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($241.6M revenue, -$25.0M net income) through FY2025, TMDX scaled operating cash flow to $192.8M and free cash flow to $133.6M, backed by $1.07B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C- • RQD 61/100): Strong cash generator (59.9% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $60.10 – $156.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 12.2x trailing P/E and 14.6x EV/EBITDA against 17.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context available is the Health Care classification and the Beta of 1.0. An investor should note that any ripple analysis would require supply-chain and correlation data not present in this dossier.

Key Question #1: Can TMDX sustain or expand its 17.9% operating margin and 18.1% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $605.5M and free cash flow of $133.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is TMDX's 10.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TMDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TransMedics Group Inc. (TMDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TMDX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

TransMedics Group (TMDX) Stock Looks Undervalued On Current Earnings

Yahoo Finance report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

TransMedics Group (Nasdaq:TMDX) - Stock Analysis

Simply Wall St report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

TransMedics Group Inc (TMDX) Stock Up 4.0% and Still Undervalued -- GF Score: 72/100

GuruFocus report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $121.10 According to Brokerages

MarketBeat report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A 4:30 p.m. ET call will accompany TransMedics' Q3 results on Nov. 5

Stock Titan report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

TransMedics Group, Inc. (TMDX) Stock Forecasts

Yahoo Finance report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

TransMedics Group (TMDX) Stock Looks Like A Bargain As Its 183% Run Continues

Simply Wall St report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

TransMedics Group (NASDAQ:TMDX) Shares Down 5.7% - Here's What Happened

MarketBeat report covering TransMedics Group Inc. (TMDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TMDX Bull vs. Bear Conversation Board — What's Your Call at $65.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TMDX 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $79.85 (+21.0%)

📌 Pinned Debate

Revenue rose from $241.6M in FY 2023 to $605.5M in FY 2025 while operating income swung to $108.6M, with a 3.5 Altman Z-Score and 8/9 P

Revenue rose from $241.6M in FY 2023 to $605.5M in FY 2025 while operating income swung to $108.6M, with a 3.5 Altman Z-Score and 8/9 Piotroski F-Score.. When you look under the hood at TMDX, Fundamental Cash Engine is 15/20 with 59.9% gross margins and 18.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (4/20) has been quietly accumulating below $156.00. My 12M target is $79.85.

ArenaChamp_24 🐂 BULL

@MidwestValue Agree on the RQD 61/100 quality, though with 1.0 beta I'm scaling in with half-size at $65.99 and keeping dry powder in case we test $61.37.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $55.43 (-16.0%)

Spot @ $65.99

Institutional accumulation scores only 4 of 20 in the RQD rating, and the stock's 52-week range of $60.1 to $156 shows a steep drawdown

Here is the bear case nobody on the bull side wants to address on TMDX: Institutional accumulation scores only 4 of 20 in the RQD rating, and the stock's 52-week range of $60.1 to $156 shows a steep drawdown from its high.. At 12.2x trailing P/E, even a small guidance miss in Biotechnology: Electromedical & Electrotherapeutic Apparatus triggers a 12-15% air pocket.